Jafron Biomedical Co Ltd
300529
Company Profile
Business description
Jafron Biomedical Co Ltd is a China-based company engaged in the research, development, production, and sales of biomaterials and medical devices. It offers solutions for kidney disease, poisoning, rheumatic immune solution, critical illness and liver disease. The company's products include JFYC-100 pre-punching machine, DX-10 blood purifier, and HA resin hemoperfusion.
Contact
No. 98, Science and Technology 6th Road
High-tech Zone
Guangdong Province
Zhuhai519085
CHNT: +86 7563619693
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
2,797
Stocks News & Analysis
stocks
Another incredible quarter from Microsoft
We were wrong when we thought last quarter would be hard to top.
stocks
10 best US dividend aristocrats to buy now—including a surprise outperformer
These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.
stocks
Leading ASX players in this field look materially overvalued
We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,917.10 | 81.90 | -0.91% |
| CAC 40 | 7,625.28 | 146.69 | -1.89% |
| DAX 40 | 23,684.34 | 381.13 | -1.58% |
| Dow JONES (US) | 44,130.98 | 330.30 | -0.74% |
| FTSE 100 | 9,086.56 | 46.25 | -0.51% |
| HKSE | 24,507.81 | 265.52 | -1.07% |
| NASDAQ | 21,122.45 | 7.23 | -0.03% |
| Nikkei 225 | 40,799.60 | 270.22 | -0.66% |
| NZX 50 Index | 12,729.40 | 94.34 | -0.74% |
| S&P 500 | 6,339.39 | 23.51 | -0.37% |
| S&P/ASX 200 | 8,662.00 | 80.80 | -0.92% |
| SSE Composite Index | 3,559.95 | 13.26 | -0.37% |